Skip to main content
. 2012 Aug 14;7(8):e43244. doi: 10.1371/journal.pone.0043244

Figure 4. Effects of intragastric infusion of Olanzapine on liver insulin sensitivity (Experiment 2).

Figure 4

(Vehicle group n = 8, Olanzapine group n = 7) 4a: Endogenous glucose production at basal (mean of 3 time points: t = 90 to t = 100; white bars) and during the hyperinsulinemic state (mean of 5 time points: t = 250 to t = 290; black bars). EGP significantly decreased during the hyperinsulinemic state for the vehicle group (p = 0.018, One-Way ANOVA) and remained unchanged in the Olanzapine group (p = 0.111, One-Way ANOVA). 4b: Glucose uptake at basal (mean of 3 time points: t = 90 to t = 100; white bars) and during the hyperinsulinemic state (mean of 5 time points: t = 250 to t = 290; black bars). Glucose uptake is significantly increased in both the vehicle (p = 0.002, One-Way ANOVA) and Olanzapine group (p = 0.046, One-Way ANOVA). 4c: Plasma corticosterone levels were significantly elevated by the IG infusion of Olanzapine (ANOVA repeated measures; Time, p<0.001; Time * Group, p<0.001; Group, p = 0.039). Vehicle-treated animals  =  white dots; Olanzapine-treated animals  =  black dots. 4d: Plasma insulin levels were elevated 1.3-fold during the hyperinsulinemic state (mean of 3 time points; black bars) compared to the basal level (mean of 2 time points; white bars) (ANOVA repeated measures; Time, p = 0.062; Time * Group, p = 0.956; Group, p = 0.706). *p<0.05,**p<0.001.